Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Celltrion Obtains US Formulation Patent for Subcutaneous Infliximab (Zymfentra®)

Apr 11, 2024

On 11 April 2024, Business Korea published that Celltrion has been granted a formulation patent (US 11 951 207) for its ZYMFENTRA®. ZYMFENTRA® is the world’s first self-developed subcutaneous injection of infliximab for treating autoimmune diseases.  Celltrion claims to have exclusive rights to its subcutaneous formulation until the patent’s “expiration in 2038”.

On 17 March 2024, Celltrion USA launched ZYMFENTRA™ (infliximab-dyyb), the first US Approved subcutaneous formulation of infliximab (approved by the U.S. FDA in 2023).